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Abstract The aim of his study was to assess the treatment
results and prognostic factors in patients with parotid gland
carcinoma. The material consisted of 109 patients treated
surgically, with or without complementary radiotherapy,
between 1978 and 2008 (follow-up at least 5-years). 5-year
overall and disease-speciWc survival were observed in
57.0% of the patients and 5-year disease-free survival was
achieved in 50.0%. Univariate analysis including ten clini-
cal and pathological features to assess their prognostic
value was done. Parapharyngeal space invasion, facial
nerve palsy, and high grade of tumor malignancy were the
factors with the highest inXuence on the treatment results,
because their presence decreased the chance for recovery
9.8, 9.7, and 8.2 times, respectively. Histologically positive
cervical lymph nodes and extraparenchymal extension were
the other factors connected with poor prognosis (prognosis
worse 6.7 and 5.4 times, respectively). Clinically positive
cervical lymph nodes, positive/uncertain microscopic mar-
gin, involvement of the deep lobe, or the whole gland
increased the risk of treatment failure 3.4, 3.1, and 2.8,
respectively. The age ¸60 years and male gender were sta-
tistically signiWcant factors, correlated with poor prognosis
and decreased chance for recovery 2.4 and 2.6 times. T-sta-
tus and clinical stage had important inXuence on 5-year dis-
ease-free survival rate because there were signiWcant
diVerences in the treatment results between individual
stages. Multivariate analysis proved that the independent
prognostic value, among anatomic structures involved by
the neoplasm, had mandible, facial nerve, and skin inWltra-
tion. Among tumor-related factors, T-stage and grade had
the statistically signiWcant inXuence on treatment results,
and stage and lymph nodes metastases among clinical and
pathological features. These results conWrm the value of
actually used TNM classiWcation (2002). Although the
parapharyngeal space invasion is a factor, which seems to
have a signiWcant, poor prognostic value, it was not
included in this classiWcation.
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Introduction
Parotid gland carcinoma is rare; it constitutes less than 3%
of all malignant head and neck tumors [1, 2]. This is the
reason why determining its prognostic factors basing on a
large group of patients is very diYcult or even impossible.
Until now several factors have been recognized to have
inXuence on prognosis and treatment outcome in patients
with parotid carcinoma, and this made the TNM classiWca-
tion to evolve [3, 4]. In actually used TNM classiWcation
(UICC 2002), T-stage is based on tumor size, presence of
extraparenchymal extension, and anatomic structures inva-
sion (Table 1) [5]. Despite its big clinical usefulness, it
seems that this classiWcation needs to be improved.
Patients and methods
The material consists of 109 patients treated for primary
parotid carcinoma at Department of Otolaryngology of Med-
ical University of Gdansk in the years 1978–2008, for whom
the follow-up period was at least 5-years. Clinical staging
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of parotid carcinomas was based on TNM classiWcation of
UICC from 2002. ReclassiWcation was done by verifying
the patient data containing results of clinical, imaging
(ultrasound, CT, MRI) and pathological examinations as
well as surgical protocols. Histological reclassiWcation was
possible in 72 patients (66%). Tumor grading was done
based on original pathological reports or redone micro-
scopic examination of the tumor.
The analyzed group consisted of 56 females (51.4%) and
53 males (48.6%). The patient age ranged from 11 to 90
years (median 58.6).
In the whole material the second (T2) and the fourth (T4)
stage was predominating–35 (32.1%) and 48 (44.0%)
patients, respectively. T1 stage was found in 11 (10.1%)
patients and T3 in 15 (13.8%). Clinical assessment of cervi-
cal lymph nodes was done by palpation; in 78 patients it
was followed by ultrasonography or computed tomography
(CT). In 75 (68.8%) patients the cervical lymph nodes were
clinically N0. N1 and N2 stage was found in 20 (18.3%)
and 14 (12.9%) patients, respectively. N3 stage was not
observed in any case. There was a predominance of high-
grade carcinomas––76 (69.7%) cases, intermediate- and
low-grade carcinomas were found in 8 (7.3%) and 25
(22.9%) patients, respectively. The most common carci-
noma were as follows: adenocarcinoma (not other speci-
Wed)––22 patients (20.2%), carcinoma ex pleomorphic
adenoma––21 patients (19.3%), mucoepidermoid carci-
noma––20 patients (18.3%), and adenoid cystic carcinoma–
–18 patients (16.5%). The remaining types: acinic cell
carcinoma, undiVerentiated carcinoma, squamous cell
carcinoma, salivary duct carcinoma, sebaceous carcinoma,
basal cell carcinoma, clear cell carcinoma, and papillary
cystadenocarcinoma were found in 28 patients (25.7%).
All patients underwent surgical treatment; 62 of them
(56.9%) had supplementary radiotherapy. In most patients
treated with combined therapy, there was at least one indi-
cation for adjuvant radiotherapy. The complementary treat-
ment was needed most frequently because of advanced
tumor stage (T3/T4) and high-malignacy grade (59 and 60
patients, respectively) as well as the presence of metastases
to regional lymph nodes (37 cases) and positive or uncer-
tain surgical margins (29 patients).
Conservative parotidectomy (with the facial nerve pres-
ervation) was performed in 44 patients (40.4%), semicon-
servative (with preservation of some facial nerve
branches)––in 17 (15.6%), and radical (with facial nerve
sacriWce) in 48 patients (44.0%). In 91 patients (83.5%) the
parotid surgery was associated with the neck dissection, it
was mostly selective neck dissection of levels II, III, and V
(67 patients––73.6%), which was performed only in
patients with clinically N0 neck. The remaining patients
underwent radical or modiWed radical neck dissection.
In 37 of these patients (40.6%) microscopic examination
proved the presence of metastases in the regional lymph
nodes and in 20 of them (30%) the neck was assessed as
N0. Nodal metastases were the most frequent in mucoepi-
dermoid carcinoma, adenocarcinoma (not other speciWed),
and carcinoma ex pleomorphic adenoma––52.4, 50.0, and
47.4%, respectively. In the fourth frequent tumor–adenoid
cystic carcinoma the cervical lymph nodes were involved
only in 14.3% of patients. In the remaining tumors nodal
metastases were remarkably present in salivary duct carci-
noma (two out of three cases).
To assess the prognostic value of some selected clinical
and pathological factors the univariate and multivariate
analyses were done. The recovery criterion was 5-year dis-
ease-free survival.
The survival expectation was assessed by Kaplan–Meier
method. To compare the survival expectation between the
two groups of patients, a Wilcox test by Gehan was used.
Multivariate analysis was done using Cox proportional haz-
ard regression. The statistical signiWcance level was estab-
lished at P < .05. Assessing the prognostic factors, the odds
ratio was used for measurement of strength of the eVect.
Results
Treatment outcome
The overall survival (OS), disease-free survival (DFS), and
disease-speciWc survival (DSS) were presented in Table 2
and Fig. 1. 10- and 15-year survivals are estimated values,
as partly they are based on the censored observations.
Table 1 T stage of the major salivary glands
TNM classiWcation (UICC 2002)
Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve, except these listed under T4a and T4b. Micro-
scopic evidence alone does not constitute extraparenchymal extension for classiWcation purposes
T1 Tumor 2 cm or less in greatest dimension without extraparenchymal extension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension
T3 Tumor more than 4 cm and/or tumor having extraparenchymal extension
T4a Tumor invades skin, mandible, ear canal, or facial nerve
T4b Tumor invades base of skull, pterygoid plates, or encases carotid arteryEur Arch Otorhinolaryngol (2012) 269:1019–1025 1021
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In analyzed material of 109 patients, the 5-year DSS was
57.0%, while 5-year DFS was 50.0%.
Estimated value of 10- and 15-year DFS was 41.0 and
38.0%, respectively.
The recurrence of disease was observed in 55 patients
(50.5%). The local recurrence was found in 18 cases
(16.5%). In 16 patients (14.7%) the distant metastases
were observed during the follow-up period, without
signs of local or regional recurrence. In the following 17
cases the recurrence was multifocal (loco-regional
recurrence––5 cases, local recurrence and distant metas-
tasis––4 cases, regional recurrence and distant metasta-
sis––3 cases, loco-regional recurrence and distant
metastasis––5 cases). Isolated regional recurrence was
found only in four cases (3.7%). Nodal recurrence was
observed in 17 patients: in 13 (14.3%) of them after pre-
viously performed neck dissection, and in 4 (22.2%)
without neck treatment.
Most of recurrences (45 cases––81.8%) were observed
during the Wrst 3 years of follow-up period.
Prognostic factors
Univariate analysis
Univariate analysis proved that the biggest inXuence on
treatment results had the following factors: invasion of the
parapharyngeal space and facial nerve paresis––nearly by
ten times worsening the prognosis. Treatment results
according to the presence of the parapharyngeal space inva-
sion are presented at the Fig. 2. Poor prognosis was also
associated with the high grade of tumor and the presence of
nodal metastases, worsening the treatment outcome by 8.2
and 6.7 times, respectively. The remaining clinical and
pathological factors, signiWcantly worsening the prognosis
(from 5.4 to 2.4 times) were extraparenchymal extension,
clinically N + neck, uncertain/positive surgical margin, pri-
mary tumor location in the deep lobe or involving the
whole parotid tissue, male gender, and the age ¸60. These
results are summarized in Table 3.
T stage had a signiWcant inXuence on 5-year DFS, there
were signiWcant diVerences between the groups of patients
with diVerent T stages (T1––81.8%, T2––74.3%, T3––
66.7%, and T4––18.7%). T4 stage worsened the prognosis
by 12.2 times compared with T1–T3 stage.
Similar diVerences in treatment outcomes were found
between groups of patients with diVerent clinical stage (I—
88.9%), II—73.3%, III—73.2% and IV—21.5%). Patients
with clinical stage I–III had 11.4 times better prognosis
compared to patients with the IV stage. Univariate analysis
Fig. 1 Overall survival, dis-
ease-speciWc survival, disease-
free survival (diagonal lines on 
the survival curves indicate cen-
sored observations)
Table 2 5-, 10-, 15-year overall survival, disease-speciWc survival,
disease-free survival in patients with parotid gland carcinoma
5-year (%) 10-year (%) 15-year (%)
Overall survival 57.0 34.0 24.0
Disease-speciWc survival 57.0 51.0 45.0
Disease-free survival 50.0 41.0 38.01022 Eur Arch Otorhinolaryngol (2012) 269:1019–1025
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proved the signiWcant diVerence only between T4 patients
compared with T1–T3 patients (T stage) and IV stage
patients compared with I–III stage patients (clinical stage).
Multivariate analysis
Multivariate analysis of correlation between neoplastic inWl-
tration of the anatomical structures and treatment outcome
was performed (Table 4). The independent factors that had
signiWcant inXuence on 5-year DFS were inWltration of the
mandible, facial nerve, and skin. InWltration of the mandible
increased the treatment failure by 4.13 times. InWltration of
the facial nerve and skin worsened the prognosis by 2.38 and
2.04 times, respectively. The remaining investigated factors
proved to have no signiWcant value in multivariate analysis.
Table 5 presents the multivariate analysis of the correla-
tion of tumor-dependent parameters and treatment out-
come. The independent signiWcant factors for prognosis
outcome proved to be the T stage and the tumor malignancy
grade. The risk of treatment failure increased nearly twice
with the each next T stage (1.78), whereas the tumor high
grade increased it by 1.5 times. In the investigated multi-
variate analysis, N stage did not change signiWcantly the
treatment outcome.
Fig. 2 Treatment results 
according to the presence of the 
parapharyngeal space invasion
Table 3 5-year disease-free 
survival according to selected 
clinical and pathological vari-
ables in univariate analysis
5-year disease-free 
survival (%)
Odds 
ratio
95% conWdence 
interval
P value
Parapharyngeal space invasion 11.8 9.8 2.1–45.1 0.0007
Facial nerve paresis/paralysis 13.0 9.7 2.7–35.2 0.0008
High grade 35.5 8.2 3.0–22.2 0.0001
Histologically positive cervical 
lymph nodes
18.9 6.7 2.5–18.1 0.0007
Extraparenchymal extension 28.0 5.4 2.4–12.3 0.0003
Clinically positive cervical 
lymph nodes
29.4 3.4 1.4–8.1 0.005
Positive microscopic margin 30.0 3.1 1.3–7.6 0.012
Deep lobe/whole gland 38.3 2.8 1.3–6.0 0.009
Male gender 37.7 2.6 1.2–5.5 0.016
Age (¸60 years) 38.9 2.4 1.1–5.1 0.027Eur Arch Otorhinolaryngol (2012) 269:1019–1025 1023
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The correlation between clinical and pathological
parameters and treatment outcome in multivariate analysis
is presented in Table 6. Independent signiWcant prognostic
factors were age, clinical stage and neck lymph nodes
metastases. The risk of treatment failure increased by 1.02
times with each passing year. Each subsequent, higher clin-
ical stage increased the risk of disease recurrence by 1.82
times, whereas the presence of nodal metastases increased
it by 2.29 times. The remaining investigated factors did not
have signiWcant prognostic value.
Discussion
Despite a long period of time from which the analyzed
material comes from, the principles for treating patients
with malignant parotid gland tumors in our department
were the same. Although in the 80s parotidectomies with
the facial nerve sacriWce and radical neck dissections were
performed more frequently, after 1990 began to prevail
operations with preservation of all or part of the seventh
nerve and the functional/selective neck dissections, which
is consistent with the trend of preservative surgery in the
past 30 years.
In published papers, 5-year DFS was higher than in our
material (50.0%) and ranged from 60 to 77% [6–9].
According to literature, 5-year DSS of patients with parotid
carcinoma was from 59 to 72% and OS, from 52 to 71% [6,
10–12]. In the material of Carrillo et al. 10-year OS and
DFS were 74 and 60%, respectively––these results are
much better than ours [13]. The worse treatment results in
our material might be explained by higher percentage of
patients with III and IV clinical stage and high-grade carci-
nomas, and thus higher risk of locoregional recurrence and/
or distant metastases. It is interesting that during the 5-year
follow-up all the deaths were associated with salivary gland
cancer (OS was equal to DSS). However, during the 10-
and 15-year follow-up, the overall survival was far lower
than those dependent on the disease (34 vs 51% and 24 vs
45%) which was probably related to the age of treated
patients and their concomitant diseases.
Predominance of high-grade carcinomas (clinically more
aggressive ones) in our material had signiWcant inXuence
on clinical signs (high clinical stage) and treatment results.
But this high proportion of patients (nearly 70%) with high-
grade carcinoma corresponds with the Wndings of other
authors (from 41 to 73%) [9, 10, 14, 15]. Worse results
would be associated with the presence of undetectable
(occult) distant metastases, as most of the patients before
surgery had only routine radiograph of the chest. More
careful diagnostic (bone scanning, abdominal ultrasound
examination and CT scan of the thorax or brain) was per-
formed from the breakthrough of the 80s and 90s and only
in cases suspected for distant metastases. Nowadays, these
examinations are performed in all patients with the high
clinical stage (III and IV) when the patient is considered for
surgical treatment.
In our opinion the extensive follow-up in order to detect
distant metastases is not really necessary, as this has no
eVect on survival. It is much more important to control
(palpations, ultrasound/CT) the tumor site and neck lymph
nodes, and the early intervention in cases of loco-regional
recurrences.
The authors support the necessity of postoperative radio-
therapy (eventually combined with chemotherapy) in cases
Table 4 Multivariate analysis
Association of anatomical structures involved by the neoplasm with
recovery
Hazard 
ratio
95% conWdence 
interval
P value
Mandible invasion 4.13 1.22–13.92 0.022
Facial nerve invasion 2.38 1.38–4.11 0.002
Skull base invasion 2.25 0.45–11.26 0.323
Skin invasion 2.04 1.04–4.00 0.037
Parapharyngeal 
space invasion
1.76 0.86–3.57 0.120
Masseter muscle invasion 1.52 0.80–2.89 0.202
External auditory 
canal invasion
1.06 0.40–2.79 0.909
Table 5 Multivariate analysis
Association of tumor related factors with recovery
Hazard ratio 95% conWdence 
interval
P value
T stage 1.78 1.29–2.45 0.0005
N stage 1.48 0.84–2.61 0.170
Tumor grade 1.47 1.12–1.92 0.006
Table 6 Multivariate analysis
Association of selected clinical and pathological variables with
recovery
Hazard 
Ratio
95% ConWdence 
Interval
P Value
Age ¸ 60 years 1.02 1.00–1.04 0.018
Male gender 1.58 0.90–2.79 0.114
Clinical stage 1.82 1.26–2.62 0.001
Histologically positive 
cervical lymph nodes
2.29 1.26–4.14 0.006
Positive/uncertain 
microscopic margin
1.06 0.83–1.55 0.7471024 Eur Arch Otorhinolaryngol (2012) 269:1019–1025
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of low-diVerentiated/high-malignancy carcinomas, high
clinical stage, nodal metastases, incomplete or close resec-
tion, and perineural or bone invasion, as according to litera-
ture it improved loco-regional control [15, 16].
Surprisingly high proportion of nodal metastases, espe-
cially occult, in our patients corresponds to that from litera-
ture (from 9 to 53%), and in N0 cases from 9 to 48% of
patients [8–11, 15, 17–22]. According to literature, the risk
of nodal involvement in parotid carcinoma is related to its
grade, microscopic structure (the highest in adenocarci-
noma not other speciWed, mucoepidermoid carcinoma,
undiVerentiated, and squamous cell carcinoma), T stage
(tumor size, facial nerve involvement, and extraparenchy-
mal inWltration) [7, 12, 17, 19–22].
Our own experience and the results of other authors
proved that neck dissection (elective or therapeutic) in
parotid gland carcinoma should be performed, especially in
cases with advanced T stage, high-grade tumors and when
microscopic structure is related to the high risk of nodal
metastases (when such information was obtained in the Wne
needle or frozen section biopsy). Since our paper was based
on retrospective data, the analysis of metastatic nodes in
individual neck levels was not possible. We think that in
clinically N0 neck the elective neck dissection should cover
levels II, III, and V, although in the material of Armstrong
et al. the occult metastases involved also levels I and IV,
which might suggest the need of radical modiWed neck dis-
section also in cases with unsuspicious cervical nodes [20].
The results of univariate analysis of the other authors
conWrm ours. According to literature, signiWcant inXuence
on 5-year survival had the following factors: age, male gen-
der, facial nerve palsy, T stage, N stage, clinical stage,
tumor grade, presence of nodal metastases, surgical margin,
and extraparenchymal extension [6–9, 11–15, 17, 18, 21,
23]. Moreover, in many papers there are signiWcant diVer-
ences in treatment outcome related to histological structure
of carcinoma [6, 11–13, 18, 21]. Witten et al. and Pedersen
et al. [8, 19] proved that carcinoma ex pleomorphic ade-
noma had the worst prognosis. Due to the fact that deW-
nitely stronger inXuence on treatment outcome had the
tumor malignancy grade than its microscopic structure, and
because of large number of histological diagnoses (12
diVerent types), and small number of some cases we did not
conduct a similar analysis.
Pohar et al. [15] found in univariate analysis that peri-
neural inWltration was a signiWcant prognostic factor. In our
material we found a particular bad prognosis in patients
with T4 stage and IV clinical stage. In T4 patients (a and b
together), 10-year DFS was not observed in any patient,
which conWrms the prognostic value of inWltration of men-
tioned anatomic structures. In our results we did not
observe a big diVerence; moreover, during the longer fol-
low-up period, we found reversal of the survival curve,
between T2 and T3 stages. Partly it could be explained by
the fact that criterion for T2 and T3 is the tumor size
(·4 cm >) and when tumor has the border size (around
4 cm), the groups do not diVer much.
Multivariate analyses presented by other authors proved
to be signiWcant the following prognostic factors: age, T
stage, N stage, clinical stage, tumor grade, presence of
nodal metastases, surgical margin, and extraparenchymal
extension [7, 11, 12, 14, 15, 17, 18, 20, 21]. Terhaard et al.
[23] showed that facial nerve paresis is an independent fac-
tor related to regional recurrence rate and DFS. Poorten
et al. [24, 25] created four stages prognostic scale based on
pre- and postoperative factors, such as age, pain, facial
nerve function, T stage, N stage, clinical stage, surgical
margin, skin, and perineural inWltration.
We did not Wnd in the literature any analyses that would
consider parapaharyngeal space invasion as poor prognostic
factor, although in our univariate analysis it was remarkably
worsening the prognosis. Multivariate analysis did not show
a statistically signiWcant eVect of inWltration of this anatomi-
cal structure on the treatment outcome. However, it also did
not conWrm the prognostic signiWcance of other well-known
parameters––including inWltration of the skull base, which
was related to their rare occurrence in this group of patients.
The authors conclude that despite technical diYculties in per-
forming radical surgery, parapharyngeal space invasion
should be included into stage T4a of TNM classiWcation of
malignant tumors of the major salivary glands.
Conclusions
Our results proved that the facial nerve paresis/palsy and
inWltration of the skin or mandible worsen the treatment
results. This conWrms the value of actually used TNM clas-
siWcation (2002). The parapharyngeal space invasion is a
factor which was not included in this classiWcation and
which seems to have a signiWcant, poor prognostic value.
Among the nonanatomical factors, the high grade of malig-
nancy of the tumor seems to have the greatest impact on
treatment outcomes.
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